EMEA-001493-PIP03-18

Key facts

Invented name
Xalkori
Active substance
crizotinib
Therapeutic area
Oncology
Decision number
P/0399/2019
PIP number
EMEA-001493-PIP03-18
Pharmaceutical form(s)
  • Capsule, hard
  • Age-appropriate oral dosage form
Condition(s) / indication(s)
  • Treatment of anaplastic large cell lymphoma
  • Treatment of inflammatory myofibroblastic tumours
Route(s) of administration
Oral use
Contact for public enquiries
Pfizer Europe MA EEIG

Tel. +44 1304 6466 07
E-mail: pip_enquiries@pfizer.com

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating